Eradicating HIV-1 infection: seeking to clear a persistent pathogen (original) (raw)

• Persaud, D. in 20th International AIDS Conference. Symposium presentation MOSY0501 (International AIDS Society, 2014).
  Google Scholar
• Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319–327 (2014).
  Article PubMed PubMed Central Google Scholar
• Chun, T. W. et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nature Med. 1, 1284–1290 (1995).
  Article CAS PubMed Google Scholar
• Chun, T. W. et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869–8873 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Strain, M. C. et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191, 1410–1418 (2005).
  Article CAS PubMed Google Scholar
• Archin, N. M. et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl Acad. Sci. USA 109, 9523–9528 (2012).
  Article PubMed PubMed Central Google Scholar
• Swiggard, W. J. et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J. Virol. 79, 14179–14188 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Bukrinsky, M. I., Stanwick, T. L., Dempsey, M. P. & Stevenson, M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254, 423–427 (1991). This paper identifies resting T lymphocytes as a major reservoir of HIV-1 infection in which the virus can be reactivated following cell stimulation.
  Article CAS PubMed Google Scholar
• Zack, J. A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213–222 (1990).
  Article CAS PubMed Google Scholar
• Zhou, Y., Zhang, H., Siliciano, J. D. & Siliciano, R. F. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J. Virol. 79, 2199–2210 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Med. 9, 727–728 (2003). This study reports that the HIV-1 reservoir is highly stable and decays very slowly in successfully treated patients receiving ART with stably undetectable plasma HIV-1 RNA.
  Article CAS PubMed Google Scholar
• Calvanese, V., Chavez, L., Laurent, T., Ding, S. & Verdin, E. Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology 446, 283–292 (2013).
  Article CAS PubMed Google Scholar
• Hermankova, M. et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J. Virol. 77, 7383–7392 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Iglesias-Ussel, M., Vandergeeten, C., Marchionni, L., Chomont, N. & Romerio, F. High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J. Virol. 87, 9148–9158 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Josefsson, L. et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc. Natl Acad. Sci. USA 110, 25 (2013).
  Article CAS Google Scholar
• Kearney, M. F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 105, 3879–3884 (2008).
  Article PubMed PubMed Central Google Scholar
• Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282, 1627–1632 (1999).
  Article CAS PubMed Google Scholar
• Grossman, Z. et al. Ongoing HIV dissemination during HAART. Nature Med. 5, 1099–1104 (1999).
  Article CAS PubMed Google Scholar
• Frenkel, L. M. et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J. Virol. 77, 5721–5730 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Med. 16, 460–465 (2010).
  Article CAS PubMed Google Scholar
• Sigal, A. et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95–98 (2011).
  Article CAS PubMed Google Scholar
• Permanyer, M. et al. Antiretroviral agents effectively block HIV replication after cell-to-cell transfer. J. Virol. 86, 8773–8780 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Agosto, L. M., Zhong, P., Munro, J. & Mothes, W. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Pathog. 10, e1003982 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Titanji, B. K., Aasa-Chapman, M., Pillay, D. & Jolly, C. Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology 10, 1742–4690 (2013).
  Article CAS Google Scholar
• Yukl, S. A. et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24, 2451–2460 (2010).
  Article CAS PubMed Google Scholar
• Vallejo, A. et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 26, 1885–1894 (2012).
  Article CAS PubMed Google Scholar
• Gandhi, R. T. et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Def. Syndr. 59, 229–235 (2012).
  Article CAS Google Scholar
• Fletcher, C. V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl Acad. Sci. USA 111, 2307–2312 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Anton, P. A. et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses 28, 1412–1421 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Robbins, B. L., Nelson, S. R. & Fletcher, C. V. A novel ultrasensitive LC–MS/MS assay for quantification of intracellular raltegravir in human cell extracts. J. Pharm. Biomed. Anal. 70, 378–387 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kieffer, T. L. et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189, 1452–1465 (2004).
  Article CAS PubMed Google Scholar
• Bailey, J. R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80, 6441–6457 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Evering, T. H. et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 8, e1002506 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Med. 15, 893–900 (2009).
  Article CAS PubMed Google Scholar
• Bosque, A., Famiglietti, M., Weyrich, A. S., Goulston, C. & Planelles, V. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog. 7, 6 (2011).
  Article CAS Google Scholar
• Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Wagner, T. A. et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570–573 (2014). References 35 and 38 show that HIV-1 integrates into genes associated with cellular proliferation, which may contribute to aberrant proliferation of silenced HIV-1 genomes.
  Article CAS PubMed PubMed Central Google Scholar
• Margolis, D. & Bushman, F. HIV/AIDS. Persistence by proliferation? Science 345, 143–144 (2014).
  Article CAS PubMed Google Scholar
• Lewinski, M. K. et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 79, 6610–6619 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Shan, L. et al. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J. Virol. 85, 5384–5393 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sherrill-Mix, S. et al. HIV latency and integration site placement in five cell-based models. Retrovirology 10, 1742–4690 (2013).
  Article CAS Google Scholar
• Verdin, E., Paras, P. Jr & Van Lint, C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12, 3249–3259 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Keedy, K. S. et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J. Virol. 83, 4749–4756 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Friedman, J. et al. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J. Virol. 85, 9078–9089 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mbonye, U. & Karn, J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 454–455, 328–339 (2014).
• du Chene, I. et al. Suv39H1 and HP1γ are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 26, 424–435 (2007).
  Article CAS PubMed Google Scholar
• Herrmann, C. H. & Rice, A. P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69, 1612–1620 (1995).
  CAS PubMed PubMed Central Google Scholar
• Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H. & Jones, K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451–462 (1998).
  Article CAS PubMed Google Scholar
• Budhiraja, S., Famiglietti, M., Bosque, A., Planelles, V. & Rice, A. P. Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J. Virol. 87, 1211–1220 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Van Lint, C., Bouchat, S. & Marcello, A. HIV-1 transcription and latency: an update. Retrovirology 10, 1742–4690 (2013).
  Article CAS Google Scholar
• Descours, B. et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin. Infect. Dis. 54, 1495–1503 (2012).
  Article CAS PubMed Google Scholar
• Bacchus, C. et al. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS ONE 8, e64219 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Soriano-Sarabia, N., Archin, N. & Margolis, D. in Conference on Retroviruses and Opportunistic Infections. Abstract 46 (2013).
  Google Scholar
• Zhang, J. & Crumpacker, C. S. Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution. Cell Res. 20, 745–747 (2010).
  Article PubMed Google Scholar
• Carter, C. C. et al. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 9, 223–234 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Carter, C. C. et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature Med. 16, 446–451 (2010).
  Article CAS PubMed Google Scholar
• Durand, C. M. et al. HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J. Infect. Dis. 205, 1014–1018 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Josefsson, L. et al. Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J. Infect. Dis. 206, 28–34 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Wightman, F. et al. Both CD31+ and CD31− naive CD4+ T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J. Infect. Dis. 202, 1738–1748 (2010).
  Article PubMed Google Scholar
• Buzon, M. J. et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nature Med. 20, 139–142 (2014).
  Article CAS PubMed Google Scholar
• Cieri, N. et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573–584 (2013).
  Article CAS PubMed Google Scholar
• Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nature Med. 17, 1290–1297 (2011).
  Article CAS PubMed Google Scholar
• Soriano-Sarabia, N. et al. Primary MHC-class II+ cells are necessary to promote resting Vδ2 cell expansion in response to (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate and isopentenyl pyrophosphate. J. Immunol. 189, 5212–5222 (2012).
  Article CAS PubMed Google Scholar
• Morita, C. T. et al. Structural features of nonpeptide prenyl pyrophosphates that determine their antigenicity for human γδ T cells. J. Immunol. 167, 36–41 (2001).
  Article CAS PubMed Google Scholar
• Hintz, M. et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli. FEBS Lett. 509, 317–322 (2001).
  Article CAS PubMed Google Scholar
• Poupot, M. & Fournie, J. J. Non-peptide antigens activating human Vγ9/Vδ2 T lymphocytes. Immunol. Lett. 95, 129–138 (2004).
  Article CAS PubMed Google Scholar
• Vavassori, S. et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nature Immunol. 14, 908–916 (2013).
  Article CAS Google Scholar
• Igarashi, T. et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl Acad. Sci. USA 98, 658–663 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Gartner, S. et al. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215–219 (1986).
  Article CAS PubMed Google Scholar
• Koenig, S. et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233, 1089–1093 (1986).
  Article CAS PubMed Google Scholar
• Lambotte, O. et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Def. Syndr. 23, 114–119 (2000).
  Article CAS Google Scholar
• Price, R. W. et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239, 586–592 (1988).
  Article CAS PubMed Google Scholar
• Gorry, P. R. et al. Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. J. Virol. 73, 352–361 (1999).
  CAS PubMed PubMed Central Google Scholar
• Sieweke, M. H. & Allen, J. E. Beyond stem cells: self-renewal of differentiated macrophages. Science 342, 1242974 (2013). This article reviews recent evidence indicating that, like stem cells, macrophages have self-renewing capabilities.
  Article CAS PubMed Google Scholar
• Queen, S. E. et al. Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J. Virol. 85, 9167–9175 (2011). This study determines that SIV Gag escape mutations can be found in the resting CD4+ T cell latent reservoir in the periphery and the CNS.
  Article CAS PubMed PubMed Central Google Scholar
• Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630–634 (2012). This study describes the presence and frequency of replication-competent latent HIV-1 in ART-suppressed humanized BLT mice.
  Article CAS PubMed PubMed Central Google Scholar
• Garcia-Martinez, J. in HIV Persistence During Therapy, Sixth International Workshop. Abstract 17 (IHL Press, 2013).
  Google Scholar
• Margolis, D. M. How might we cure HIV? Curr. Infect. Dis. Rep. 16, 392 (2014).
  Article PubMed Google Scholar
• Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188 (1997).
  Article CAS PubMed Google Scholar
• Yang, H. C. et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119, 3473–3486 (2009).
  CAS PubMed PubMed Central Google Scholar
• Cameron, P. U. et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc. Natl Acad. Sci. USA 107, 16934–16939 (2010).
  Article PubMed PubMed Central Google Scholar
• Saleh, S. et al. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110, 4161–4164 (2007).
  Article CAS PubMed Google Scholar
• Lassen, K. G., Hebbeler, A. M., Bhattacharyya, D., Lobritz, M. A. & Greene, W. C. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS ONE 7, e30176 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22, 1868–1877 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Bosque, A. & Planelles, V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113, 58–65 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bosque, A. & Planelles, V. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 53, 54–61 (2011).
  Article CAS PubMed Google Scholar
• Tyagi, M., Pearson, R. J. & Karn, J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84, 6425–6437 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Spina, C. A. et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9, e1003834 (2013). This study compares the responses to different latency-reactivating stimuli in nearly all of the primary cell HIV-1 latency models that have been described to responses obtained using the QVOA in cells from patients infected with HIV-1.
  Article CAS PubMed PubMed Central Google Scholar
• Hakre, S., Chavez, L., Shirakawa, K. & Verdin, E. HIV latency: experimental systems and molecular models. FEMS Microbiol. Rev. 36, 706–716 (2012).
  Article CAS PubMed Google Scholar
• Barton, K. M., Burch, B. D., Soriano-Sarabia, N. & Margolis, D. M. Prospects for treatment of latent HIV. Clin. Pharmacol. Ther. 93, 46–56 (2013).
  Article CAS PubMed Google Scholar
• Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nature Rev. Immunol. 7, 118–130 (2007).
  Article CAS Google Scholar
• Lan, P., Tonomura, N., Shimizu, A., Wang, S. & Yang, Y. G. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 108, 487–492 (2006).
  Article CAS PubMed Google Scholar
• Melkus, M. W. et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nature Med. 12, 1316–1322 (2006).
  Article CAS PubMed Google Scholar
• Denton, P. W. et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5, e16 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Brainard, D. M. et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J. Virol. 83, 7305–7321 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Denton, P. W. et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE 5, e8829 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Marsden, M. D. et al. HIV latency in the humanized BLT mouse. J. Virol. 86, 339–347 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Long, B. R. & Stoddart, C. A. α-interferon and HIV infection cause activation of human T cells in NSG–BLT mice. J. Virol. 86, 3327–3336 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Zou, W. et al. Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. Retrovirology 9, 44 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, Z. et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. 204, 705–714 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Denton, P. W. et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 10, e1003872 (2014). In this study, an immunotoxin is evaluated for its capacity to kill HIV-1-expressing cells in a humanized mouse model. The results show a dramatic reduction in HIV-1 RNA in tissue following immunotoxin administration together with ART.
  Article CAS PubMed PubMed Central Google Scholar
• Vatakis, D. N. et al. Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J. Vis. Exp. 70, e4181 (2012).
  Google Scholar
• Shimizu, S. et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115, 1534–1544 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Honeycutt, J. B. et al. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology 10, 121 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Dinoso, J. B. et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 83, 9247–9257 (2009). This study shows the frequency and distribution of replication-competent latent SIV in ART-suppressed macaques.
  Article CAS PubMed PubMed Central Google Scholar
• Clements, J. E., Gama, L., Graham, D. R., Mankowski, J. L. & Zink, M. C. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr. Opin. HIV AIDS 6, 37–42 (2011).
  Article PubMed PubMed Central Google Scholar
• Hirsch, V. M., Zack, P. M., Vogel, A. P. & Johnson, P. R. Simian immunodeficiency virus infection of macaques: end-stage disease is characterized by widespread distribution of proviral DNA in tissues. J. Infect. Dis. 163, 976–988 (1991).
  Article CAS PubMed Google Scholar
• Horiike, M. et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 423, 107–118 (2012).
  Article CAS PubMed Google Scholar
• Baskin, G. B. et al. Distribution of SIV in lymph nodes of serially sacrificed rhesus monkeys. AIDS Res. Hum. Retroviruses 11, 273–285 (1995).
  Article CAS PubMed Google Scholar
• Shen, A. et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus–Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J. Virol. 77, 4938–4949 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Clements, J. E. et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J. Infect. Dis. 186, 905–913 (2002).
  Article CAS PubMed Google Scholar
• Clements, J. E. et al. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J. Neurovirol. 11, 180–189 (2005).
  Article CAS PubMed Google Scholar
• Zink, M. C. et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J. Infect. Dis. 202, 161–170 (2010).
  Article CAS PubMed Google Scholar
• Van Rompay, K. K. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 85, 159–175 (2010).
  Article CAS PubMed Google Scholar
• Deere, J. D. et al. Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART. PLoS ONE 9, e87914 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• North, T. W. et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 84, 2913–2922 (2010).
  Article CAS PubMed Google Scholar
• Schmitz, J. E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860 (1999).
  Article CAS PubMed Google Scholar
• Hansen, S. G. et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874 (2013).
  Article CAS PubMed Google Scholar
• Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Mavigner, M. et al. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. Abstract 416 (2014).
• Kiem, H. P. et al. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. Abstract 419 (2014).
• Spivak, A. M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883–890 (2014).
  Article CAS PubMed Google Scholar
• Prins, J. M. et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13, 2405–2410 (1999).
  Article CAS PubMed Google Scholar
• Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207–212 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782–6789 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kauder, S. E., Bosque, A., Lindqvist, A., Planelles, V. & Verdin, E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5, e1000495 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Blazkova, J. et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5, e1000554 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D. & Siliciano, R. F. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature Med. 20, 425–429 (2014).
  Article CAS PubMed Google Scholar
• Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol. 21, 277–285 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Rasmussen, T. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. 22, e-1 Abstract 438LB (2014).
  Google Scholar
• Elliot, J. et al. in Highlights of the 20th conference on retroviruses and opportunistic infections. Top. Antivir. Med. 21 Abstract 50LB (2013).
  Google Scholar
• Wei, D. G. et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 10, e1004071 (2014). This study characterizes the ability of the HDAC inhibitor romidepsin to induce HIV-1 expression in vitro in CD4+ T cells isolated from aviraemic patients infected with HIV-1.
  Article PubMed PubMed Central Google Scholar
• Archin, N. M. et al. HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat. J. Infect. Dis. 210, 728–735 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, K. et al. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. 22, e-1 Abstract 435 (2014).
  Google Scholar
• Graf, E. H. et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS ONE 8, e71879 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013). This study reports that, although ∼90% of non-induced proviruses in the QVOA are defective, ∼11.7% of these non-induced proviruses have intact genomes, which suggests that the QVOA may underestimate the true size of the latent reservoir in some patients.
  Article CAS PubMed PubMed Central Google Scholar
• Burnett, J. C. et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol. 84, 5958–5974 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Reuse, S. et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 4, 0006093 (2009).
  Article CAS Google Scholar
• Bernhard, W. et al. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett. 585, 3549–3554 (2011).
  Article CAS PubMed Google Scholar
• Fernandez, G. & Zeichner, S. L. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol. J. 7, 266 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chou, T. C. Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res. 70, 440–446 (2010).
  Article CAS PubMed Google Scholar
• Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491–501 (2012). This study found that reversal of HIV-1 latency did not result in uniform cell clearance in an in vitro model system and shows that stimulation of CTLs with HIV-1 peptides improves the recognition and killing of infected cells in vitro.
  Article CAS PubMed PubMed Central Google Scholar
• Khaitan, A. & Unutmaz, D. Revisiting immune exhaustion during HIV infection. Curr. HIV/AIDS Rep. 8, 4–11 (2011).
  Article PubMed PubMed Central Google Scholar
• Moir, S. et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205, 1797–1805 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Goulder, P. J. & Watkins, D. I. HIV and SIV CTL escape: implications for vaccine design. Nature Rev. Immunol. 4, 630–640 (2004).
  Article CAS Google Scholar
• Papuchon, J. et al. Resistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccine. PLoS ONE 8, e69029 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Garcia, F., Leon, A., Gatell, J. M., Plana, M. & Gallart, T. Therapeutic vaccines against HIV infection. Hum. Vaccin. Immunother. 8, 569–581 (2012). This review summarizes the different types of HIV-1 vaccines that have been developed so far, highlighting the main characteristics of each and clinical trials when applicable.
  Article CAS PubMed Google Scholar
• Gay, C. et al. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. 22, e-1 Abstract 344 (2014).
  Google Scholar
• Casazza, J. P. et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 207, 1829–1840 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Chapuis, A. G. et al. HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood 117, 5391–5402 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sung, J. et al. in Sixth International Workshop on HIV Persistence during Therapy Abstract 58 (IHL Press, 2013).
  Google Scholar
• Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44–49 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Groscurth, P. Cytotoxic effector cells of the immune system. Anat. Embryol. 180, 109–119 (1989).
  Article CAS Google Scholar
• Hudspeth, K. et al. Engagement of NKp30 on Vδ1 T cells induces the production of CCL3, CCL4, and CCL5 and suppresses HIV-1 replication. Blood 119, 4013–4016 (2012).
  Article CAS PubMed Google Scholar
• Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N. & Zitvogel, L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nature Immunol. 9, 486–494 (2008).
  Article CAS Google Scholar
• Steel, J. C., Waldmann, T. A. & Morris, J. C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33, 35–41 (2012).
  Article CAS PubMed Google Scholar
• Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844–3855 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bonsignori, M. et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11521–11532 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Varela-Rohena, A. et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Med. 14, 1390–1395 (2008). In this study, T cells were engineered to recognize HIV-1 strains that have evaded the immune system.
  Article CAS PubMed Google Scholar
• Heslop, H. E. Genetic engineering of T-cell receptors: TCR takes to titin. Blood 122, 853–854 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354 (2006).
  Article CAS PubMed Google Scholar
• Leng, Q., Bentwich, Z., Magen, E., Kalinkovich, A. & Borkow, G. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS 16, 519–529 (2002).
  Article CAS PubMed Google Scholar
• Palmer, B. E. et al. In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J. Immunol. 190, 211–219 (2013).
  Article CAS PubMed Google Scholar
• Pincus, S. H. Therapeutic potential of anti-HIV immunotoxins. Antiviral Res. 33, 1–9 (1996).
  Article CAS PubMed Google Scholar
• Davey, R. T. Jr et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J. Infect. Dis. 170, 1180–1188 (1994).
  Article PubMed Google Scholar
• Bera, T. K. et al. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol. Med. 4, 384–391 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Dadachova, E. et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med. 3, e427 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397–405 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hatano, H. et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 9, 10 (2013).
  Article CAS Google Scholar
• Myers, L. E., McQuay, L. J. & Hollinger, F. B. Dilution assay statistics. J. Clin. Microbiol. 32, 732–739 (1994).
  CAS PubMed PubMed Central Google Scholar
• Siliciano, J. D. & Siliciano, R. F. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol. Biol. 304, 3–15 (2005).
  PubMed Google Scholar
• Archin, N. M. et al. Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. 22, e-1 Abstract 406 (2014).
  Google Scholar
• Rouzioux, C. & Richman, D. How to best measure HIV reservoirs? Curr. Opin. HIV AIDS 8, 170–175 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Pasternak, A. O., Lukashov, V. V. & Berkhout, B. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 10, 1742–4690 (2013).
  Article CAS Google Scholar
• Palmer, S. et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41, 4531–4536 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Strain, M. C. & Richman, D. D. New assays for monitoring residual HIV burden in effectively treated individuals. Curr. Opin. HIV AIDS 8, 106–110 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Strain, M. C. et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS ONE 8, e55943 (2013). This paper demonstrates the ability of droplet digital PCR to reliably and accurately measure the frequency of total HIV-1 DNA and episomal 2-LTR circles in cells isolated from patients infected with HIV-1.
  Article CAS PubMed PubMed Central Google Scholar
• Kiselinova, M. et al. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. PLoS ONE 9, e85999 (2014). This paper reports the feasibility of using droplet digital PCR to measure cell-associated RNA from patients infected with HIV-1.
  Article CAS PubMed PubMed Central Google Scholar
• Sanchez, G., Xu, X., Chermann, J. C. & Hirsch, I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J. Virol. 71, 2233–2240 (1997).
  CAS PubMed PubMed Central Google Scholar
• Kieffer, T. L. et al. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol. 79, 1975–1980 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Eriksson, S. et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 9, e1003174 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Anderson, J. A. et al. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J. Virol. 85, 5220–5223 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Soriano-Sarabia, N. et al. The quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. J. Virol. http://dx.doi.org/10.1128/JVI.01900-14 (2014).